461702-08-9

Basic information

• Product Name: 1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-1H-benzo[d]imidazole
• Synonyms: 1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-1H-benzo[d]imidazole
• CAS NO: 461702-08-9
• Molecular Weight: 334.226
• Mol File: 461702-08-9.mol

Chemical Properties

• CAS DataBase Reference: 1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-1H-benzo[d]imidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-1H-benzo[d]imidazole(461702-08-9)
• EPA Substance Registry System: 1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-1H-benzo[d]imidazole(461702-08-9)

Safety Data

• Hazardous Substances Data: 461702-08-9(Hazardous Substances Data)

Upstream product

• 73183-34-3 bis(pinacol)diborane 
• 73798-61-5 1-(4-bromobenzyI)-1H-benzo[d]imidazole 

Downstream Products

• 1104736-12-0 2-(4-benzoimidazol-1-ylmethyl-phenyl)-3-methyl-3H-imidazole-4-carboxylic acid methyl ester 

Relevant articles and documents

3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3-aryl-5-substituted-2H-isoquinolin-1-one compounds that, inter alia, inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.

AMINOALKYLAZOLE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS

The present invention provides a compound of formula I: and the use thereof for the treatment of a central nervous system disorder related to or affected by the histamine-3 receptor.

Pyrazolopyrimidines as therapeutic agents

The present invention is directed to pyrazolopyrimidine derivatives of formula (I) wherein the substituents are defined herein, which are useful as kinase inhibitors and as such are useful for affecting angiogenesis and diseases and conditions associated with angiogenesis.

Pyrazolopyrimidines as therapeutic agents

The present invention provides compounds of Formula I, including pharmaceutically acceptable salts and/or prodrugs thereof, where G, R2, and R3 are defined as described herein.